drugset / Trial / NCT00176774
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM) combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV). This study will evaluate the safety and tolerability of the combination of these drugs when they are used in the treatment of metastatic colorectal cancer. This is a pilot clinical trial which will be studying the reactions of the patient's body and tumor to the experimental treatment described above. The purpose of this study is to find out what kind of side effects this experimental treatment causes and see how often these side effects occur.
Timeline
- Start
- 2001-02
- Primary completion
- 2004-02
- Completion
- 2004-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tetrathiomolybdate | Unknown | 40 mg | Oral |
| Subject | Tetrathiomolybdate | Unknown | 60 mg | Oral |
| Background | Irinotecan | Small molecule | — | Intravenous |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |